Qiagen (NYSE:QGEN) Releases FY 2024 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 2.190- for the period, compared to the consensus estimate of 2.150. The company issued revenue guidance of $2.0 billion-, compared to the consensus revenue estimate of $2.0 billion. Qiagen also updated its FY24 guidance to at least $2.19 EPS.

Qiagen Trading Down 0.2 %

Qiagen stock traded down $0.08 during mid-day trading on Wednesday, reaching $43.87. 1,601,482 shares of the company traded hands, compared to its average volume of 1,170,505. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.77 and a quick ratio of 1.46. The firm’s 50 day moving average price is $44.15 and its 200 day moving average price is $43.70. The firm has a market capitalization of $10.01 billion, a price-to-earnings ratio of 142.49, a P/E/G ratio of 3.33 and a beta of 0.41. Qiagen has a 52-week low of $37.51 and a 52-week high of $47.44.

Analyst Ratings Changes

QGEN has been the topic of a number of research analyst reports. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research report on Thursday, October 17th. HSBC cut shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a report on Thursday, October 17th. Finally, Robert W. Baird boosted their target price on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $50.88.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.